卵巢恶性肿瘤是女性生殖器官常见的恶性肿瘤之一,发病率仅次于子宫颈癌和子宫体癌,居第3位。但卵巢上皮癌死亡率却占各类妇科肿瘤的首位,对妇女生命造成严重威胁。大约2/3卵巢癌患者在进行初诊时,已属晚期,且治疗效果差[1-2]。作为目前使用最多的肿瘤标志物-肿瘤抗原125(CA125),已有许多研究表明其在卵巢癌辅助诊断及治疗后疗效观察方面的价值[3]。本文通过收集2013年5月-2014 Ovarian cancer is one of the common malignant tumors of female genital organs, the incidence of second only to cervical cancer and uterine cancer, ranking No. 3. However, the death rate of epithelial ovarian cancer has accounted for the first of all types of gynecological tumors, causing serious threat to women’s lives. About two-thirds of patients with ovarian cancer in the initial diagnosis, is already late, and the treatment of poor [1-2]. As the most widely used tumor marker, tumor antigen 125 (CA125), many studies have shown its value in the diagnosis of ovarian cancer and the efficacy of treatment after treatment [3]. This article by collecting May 2013 -2014